641 related articles for article (PubMed ID: 16424917)
1. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
Lipton SA
Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917
[TBL] [Abstract][Full Text] [Related]
2. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
3. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
4. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Lipton SA
Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
[TBL] [Abstract][Full Text] [Related]
5. Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine.
Lipton SA; Chen HS
Cell Death Differ; 2004 Jan; 11(1):18-20. PubMed ID: 14647237
[No Abstract] [Full Text] [Related]
6. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Lipton SA
Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of memantine.
Johnson JW; Kotermanski SE
Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
[TBL] [Abstract][Full Text] [Related]
8. In vitro galantamine-memantine co-application: mechanism of beneficial action.
Zhao X; Marszalec W; Toth PT; Huang J; Yeh JZ; Narahashi T
Neuropharmacology; 2006 Dec; 51(7-8):1181-91. PubMed ID: 17011596
[TBL] [Abstract][Full Text] [Related]
9. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.
Kornhuber J; Weller M; Schoppmeyer K; Riederer P
J Neural Transm Suppl; 1994; 43():91-104. PubMed ID: 7884411
[TBL] [Abstract][Full Text] [Related]
10. Synergistic neuroprotection by bis(7)-tacrine via concurrent blockade of N-methyl-D-aspartate receptors and neuronal nitric-oxide synthase.
Li W; Xue J; Niu C; Fu H; Lam CS; Luo J; Chan HH; Xue H; Kan KK; Lee NT; Li C; Pang Y; Li M; Tsim KW; Jiang H; Chen K; Li X; Han Y
Mol Pharmacol; 2007 May; 71(5):1258-67. PubMed ID: 17299028
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels.
Chen HS; Lipton SA
J Pharmacol Exp Ther; 2005 Sep; 314(3):961-71. PubMed ID: 15901795
[TBL] [Abstract][Full Text] [Related]
12. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.
Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M
Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864
[TBL] [Abstract][Full Text] [Related]
14. 3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism.
Karanian DA; Baude AS; Brown QB; Parsons CG; Bahr BA
Hippocampus; 2006; 16(10):834-42. PubMed ID: 16897723
[TBL] [Abstract][Full Text] [Related]
15. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma.
Seki M; Lipton SA
Prog Brain Res; 2008; 173():495-510. PubMed ID: 18929130
[TBL] [Abstract][Full Text] [Related]
16. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
Danysz W; Parsons CG
Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
[TBL] [Abstract][Full Text] [Related]
17. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
Lipton SA
NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
[TBL] [Abstract][Full Text] [Related]
18. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
Song MS; Rauw G; Baker GB; Kar S
Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
[TBL] [Abstract][Full Text] [Related]
19. NMDA channel blockers: memantine and amino-aklylcyclohexanes--in vivo characterization.
Danysz W; Parsons CG; Quack G
Amino Acids; 2000; 19(1):167-72. PubMed ID: 11026485
[TBL] [Abstract][Full Text] [Related]
20. Pathologically activated therapeutics for neuroprotection.
Lipton SA
Nat Rev Neurosci; 2007 Oct; 8(10):803-8. PubMed ID: 17882256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
